Floatz logo

FLUDEOXYGLUCOSE

Recurrent Glioblastoma

Jonsson Comprehensive Cancer CenterSmall moleculePhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
81/ 100

Competitive context

39 Active assets in the Recurrent Glioblastoma cohort.

Asset / SponsorPhaseRating
Cediranib
M.D. Anderson Cancer Center
Phase 3BB
Niraparib
Ivy Brain Tumor Center
Phase 3BB
Atezolizumab
Centre Hospitalier Universitaire Vaudois
Phase 2B
11.BETA.,13-DIHYDRO-13-(DIMETHYLAMINO)MICHELIOLIDE
National Neuroscience Institute
Phase 2B
Monomethyl Fumarate
Alliance for Clinical Trials in Oncology
Phase 2/3B

View all 50 →

Same molecule, other indications

FLUDEOXYGLUCOSE is also rated in:

Recurrent Adult Brain TumorDormant
BB
Indicative ·
71 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
69 / 100
View asset →
prostate carcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →